Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4288+0.0056 (+1.32%)
At close: 04:00PM EST
0.4435 +0.01 (+3.43%)
After hours: 07:10PM EST
Advertisement

Acasti Pharma Inc.

3009 boulevard de la Concorde East
Suite 102
Laval, QC H7E 2B5
Canada
450 687 2262
https://www.acastipharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Janelle D'AlvisePres, CEO, Corp. Sec. & Director620.16kN/A1955
Dr. Pierre Lemieux M.D., Ph.D.Co-Founder, COO & Chief Scientific Officer398.75kN/A1965
Mr. Brian D. Ford CPA, CAChief Financial Officer340.84kN/A1959
Dr. George KottayilChief Operating Officer of US160.16kN/A1963
Mr. Prashant KohliChief Commercial Officer185.2kN/AN/A
Dr. Yves Lachance Ph.D.VP of Quality & ComplianceN/AN/AN/A
Ms. Christine PelletierSr. Director of HRN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Corporate Governance

Acasti Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement